Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
January 06 2023 - 8:00AM
Business Wire
Will commercialize end-to-end workflow solutions for tissue
biomarker analysis in companion diagnostic development
Agilent Technologies, Inc. (NYSE: A) today announced a
partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The
Spatial Biology Company®, to develop multiplex-immunohistochemistry
diagnostic solutions for tissue analysis and to commercialize
workflow solutions for multiplex assays in the clinical research
market. Integrating Agilent’s Dako Omnis (autostaining instrument)
and Akoya’s PhenoImager® HT (imaging platform) for multiplex
chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF)
assays will create a singular end-to-end commercial workflow,
including reagents, staining, imaging, and analysis.
Agilent and Akoya will partner to develop chromogenic and
immunofluorescent multiplex assays that include spatial analysis
for biopharma companies developing precision cancer therapeutics.
These assay solutions will enable researchers and medical
professionals to address patient selection needs of novel
therapeutics and rapidly translate their discoveries into clinical
testing. Spatial phenotyping using multiplex imaging provides the
advantages of single-cell analysis while preserving spatial
relationships between the cells. This offers an invaluable tool for
uncovering novel insights into cellular organization in the tumor
microenvironment and therapeutic response.
This agreement will deliver an end-to-end multiplex solution for
biomarker clinical research enabled by digital pathology, providing
capabilities across the pharma value chain. Combining Agilent’s
companion diagnostic and IHC workflow expertise, the large install
base of Dako Omnis instruments, and a strong network of pharma
partners; with Akoya’s install base of imagers, spatial analysis
expertise, and CLIA lab capabilities will further empower biopharma
partners to leverage this integrated workflow solution for their
biomarker discovery and validation needs, helping drive better
patient stratification. Under a separate Value-Added Reseller
agreement, Akoya Biosciences will distribute and resell Dako Omnis
as a part of the end-to-end multiplex solution.
“We are delighted to be partnering with Akoya to create
industry-leading products and services for multiplex chromogenic
and immunofluorescence tissue assays,” said Sam Raha, president of
Agilent’s Diagnostic and Genomics Group. “This partnership enables
an ecosystem that assists the development of novel precision cancer
therapeutics and offers a streamlined workflow to our joint
customers in the clinical research market to meet the needs of
future clinical diagnostics,” Raha added.
“Multiplex tissue analysis has the potential to transform the
field of cancer therapeutics and usher in a new era of precision
pathology,” said Brian McKelligon, CEO of Akoya Biosciences. “This
partnership and the combined strength of both organizations will
catalyze the development and deployment of multiplex tissue-based
biomarkers for the benefit of our biopharma and CRO partners and,
ultimately, patients.“
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.85 billion in fiscal 2022 and employs 18,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230106005053/en/
Media Contacts Naomi Goumillout Agilent Technologies
+1.781.266.2819 naomi.goumillout@agilent.com Christine Quern Akoya
Biosciences +1.617.650.8497 media@akoyabio.com
Investor Contact Priyam Shah Sr. Director, Investor
Relations Akoya Biosciences investors@akoyabio.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024